3,4-Dibromo-Mal-PEG2-amine TFA

Cat. No.:	HY-141004A
CAS No.:	2296708-07-9
Molecular Formula:	$C_{12}H_{15}Br_2F_3N_2O_6$
Molecular Weight:	500.06
Target:	PROTAC Linkers
Pathway:	PROTAC
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H_2O : ≥ 100 mg/mL (199.98 mM)
DMSO : 100 mg/mL (199.98 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9998 mL	9.9988 mL	19.9976 mL
	5 mM	0.4000 mL	1.9998 mL	3.9995 mL
	10 mM	0.2000 mL	0.9999 mL	1.9998 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

3,4-Dibromo-Mal-PEG2-amine TFA is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

IC_{50} & Target

PEGs

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA